Known targets — ChEMBL curated mechanism
ACHECHKACHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGHRH2OPRM1
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | CHRNA7 | P36544 | 9/20 | 0.41 |
| ▸ | TRAP1 | Q12931 | 2/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | SNCA | P37840 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL9318288 | 0.96 | HIF1A (0.58) | HIF1AALDH1A1CYP1A2CYP2D6TSHR | |
| Bromide SCHEMBL2806321 | 0.88 | HIF1A (0.54) | HIF1AALDH1A1CYP1A2CYP2D6TSHR | |
| Iodide SCHEMBL3466381 | 0.83 | CHRNA7 (0.54) | HIF1AALDH1A1CYP1A2CYP2D6TSHR | |
| Iodide SCHEMBL1051101 | 0.82 | CHRNA7 (0.55) | HIF1AALDH1A1CYP1A2CYP2D6TSHR | |
| Bromide SCHEMBL17511368 | 0.79 | HIF1A (0.54) | HIF1AALDH1A1CYP1A2CYP2D6TSHR | |
| Phenylmethanesulfonic Acid SCHEMBL6232593 | 0.79 | HIF1A (0.40) | HIF1AALDH1A1CYP1A2CYP2D6TSHR | |
| Bromide SCHEMBL2447020 | 0.78 | HIF1A (0.94) | HIF1AALDH1A1CYP1A2CYP2D6TSHR | |
| SCHEMBL6232589 | 0.78 | ALDH1A1 (0.40) | HIF1AALDH1A1CYP1A2CYP2D6TSHR | |
| Iodide SCHEMBL9817092 | 0.77 | CHRNA7 (0.49) | HIF1AALDH1A1CYP1A2CYP2D6TSHR | |
| Bromide SCHEMBL2701958 | 0.77 | HIF1A (0.47) | HIF1AALDH1A1CYP1A2CYP2D6TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250179032-A1 | HETEROCYCLIC INHIBITORS OF GLUT9 FOR TREATMENT OF DISEASE | HORIZON THERAPEUTICS IRELAND DAC (IE) | 2025-06-05 | — | — | US | disclosed |
| CN-119013265-A | GLUT9 heterocyclic inhibitors for the treatment of disease | 爱尔兰好利恩治疗有限公司 | 2024-11-22 | — | — | CN | disclosed |
| EP-4460496-A1 | HETEROCYCLIC INHIBITORS OF GLUT9 FOR TREATMENT OF DISEASE | Horizon Therapeutics Ireland DAC (IE) | 2024-11-13 | — | — | EP | disclosed |
| WO-2023131868-A1 | HETEROCYCLIC INHIBITORS OF GLUT9 FOR TREATMENT OF DISEASE | HORIZON THERAPEUTICS IRELAND DAC (IE) | 2023-07-13 | — | — | WO | disclosed |
| CN-106488918-B | Triazolopyrimidone or triazolopyridinone derivatives and uses thereof | ST制药株式会社 | 2020-02-28 | — | — | CN | disclosed |
| EP-3166945-B1 | NOVEL TRIAZOLOPYRIMIDINONE OR TRIAZOLOPYRIDINONE DERIVATIVES, AND USE THEREOF | ST PHARM CO LTD (KR) | 2019-10-09 | — | — | EP | disclosed |
| US-9914737-B2 | Triazolopyrimidinone or triazolopyridinone derivatives, and use thereof | ST PHARM CO., LTD. (KR) | 2018-03-13 | — | — | US | disclosed |
| US-20170145016-A1 | NOVEL TRIAZOLOPYRIMIDINONE OR TRIAZOLOPYRIDINONE DERIVATIVES, AND USE THEREOF | ST PHARM CO., LTD. (KR) | 2017-05-25 | — | — | US | disclosed |
| EP-3166945-A2 | NOVEL TRIAZOLOPYRIMIDINONE OR TRIAZOLOPYRIDINONE DERIVATIVES, AND USE THEREOF | ST Pharm Co. Ltd. (KR) | 2017-05-17 | — | — | EP | disclosed |
| WO-2016006974-A2 | NOVEL TRIAZOLOPYRIMIDINONE OR TRIAZOLOPYRIDINONE DERIVATIVES, AND USE THEREOF | ST PHARM CO., LTD. (KR) | 2016-01-14 | — | — | WO | disclosed |
| EP-1717226-A1 | 2,7-SUBSTITUTED 5-AMINO-4-HYDROXY-8-(1H-INDOL-5-YL)-OCTAN AMIDE DERIVATIVES AS RENIN INHIBITORS FOR THE TREATMENT OF HYPERTENSION | Speedel Experimenta AG (CH) | 2006-11-02 | — | — | EP | disclosed |
| EP-1712548-A2 | 5-AMINO-4-HYDROXY-7-(PYRIDINYLMETHYL)-ALKANAMIDE DERIVATIVES AND RELATED COMPOUNDS AS RENIN INHIBITORS FOR THE TREATMENT OF HYPERTENSION | Speedel Experimenta AG (CH) | 2006-10-18 | — | — | EP | disclosed |
| EP-1699762-A1 | 5-AMINO-4-HYDROXY-7-(1H-INDOLMETHYL)-8-METHYLNONAMIDE DERIVATIVES AS RENIN INHIBITORS FOR THE TREATMENT OF HYPERTENSION | Speedel Experimenta AG (CH) | 2006-09-13 | — | — | EP | disclosed |
| EP-1689712-A1 | 4-PHENYLPIPERIDINE DERIVATIVES AS RENIN INHIBITORS | Novartis AG (CH) | 2006-08-16 | — | — | EP | disclosed |
| WO-2005090304-A1 | ORGANIC COMPOUNDS | SPEEDEL EXPERIMENTA AG (CH) | 2005-09-29 | — | — | WO | disclosed |
| WO-2005090305-A1 | 5-AMINO-4-HYDROXY-7-(1H-INDOLMETHYL)-8-METHYLNONAMIDE DERIVATIVES AS RENIN INHIBITORS FOR THE TREATMENT OF HYPERTENSION | SPEEDEL EXPERIMENTA AG (CH) | 2005-09-29 | — | — | WO | disclosed |
| WO-2005051911-A1 | 4-PHENYLPIPERIDINE DERIVATIVES AS RENIN INHIBITORS | NOVARTIS AG (CH) | 2005-06-09 | — | — | WO | disclosed |
| US-5719141-A | HYPOTENSIVE AGENTS | NOVARTIS CORPORATION (US) | 1998-02-17 | — | — | US | disclosed |
| EP-0702004-A2 | 2,9-diamino- and 2-amino-8-carbamoyl-4-hydroxy-alkanoic acid amid derivatives | CIBA-GEIGY AG (CH) | 1996-03-20 | — | — | EP | disclosed |
| US-4035414-A | Prostanoic acid derivatives | CARLO ERBA S.P.A. (IT) | 1977-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170145016-A1 | NOVEL TRIAZOLOPYRIMIDINONE OR TRIAZOLOPYRIDINONE DERIVATIVES, AND USE THEREOF | TNKS1BP1, TNKS, TPI1 | HIF1A 4532/4885ALDH1A1 2244/4885CYP1A2 2224/4885 |
| US-20250179032-A1 | HETEROCYCLIC INHIBITORS OF GLUT9 FOR TREATMENT OF DISEASE | SLC2A9, SLC2A1, SLC2A8 | HIF1A 480/4885ALDH1A1 745/4885CYP1A2 2802/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.